Oculis Holding AG OCS
Set alert
7.76 USD -0.50 -6.05%
As of Nov 2, 2:46 PM ET
7.73 Day range 8.54
7.11 52-week range 34.48
- YTD
- -61.14%
- 1 year
- -59.75%
- Open
- 8.38
- Prev close
- 8.26
- Mkt cap
- 478.85M
- Vol
- 103.30K
- Avg vol
- 259.08K
- EPS
- -1.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.73
- High
- 8.54
- Forward P/E
- -6.94
- Beta
- 0.20
- Short ratio
- 1.06
- Inst. own
- 37.91%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.67
- 200-d avg
- 23.22
- 1y target
- 51.82
2Y chart
Events in this range
- May 18, 2026Rating: JP Morgan · Overweight → Overweight
- May 21, 2026Rating: Guggenheim · — → Buy
- Jun 1, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jun 1, 2026Rating: Needham · Buy → Buy
- Jun 1, 2026Rating: Guggenheim · Buy → Buy
- Jun 1, 2026Rating: Stifel · Buy → Buy
Signals (82)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 24, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| RSI: Oversold | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| RSI: Oversold | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 9 months ago |
| RSI: Overbought | Jan 9, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 10 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Jan 2, 2026 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 16, 2025 | 10 months ago |
| RSI: Overbought | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| SMA: Bullish | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 13, 2025 | 11 months ago |
| SMA: Bearish | Nov 12, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 9, 2025 | 1 year ago |
| RSI: Oversold | Aug 28, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 29, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| SMA: Bearish | May 22, 2025 | 1 year ago |
| SMA: Bullish | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 21, 2025 | 1 year ago |
| SMA: Bearish | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 2, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| RSI: Oversold | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| RSI: Overbought | Jan 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 2, 2025 | 1 year ago |
Key statistics
- Market cap
- 876.23M
- Enterprise value
- 1.11B
- Trailing P/E
- 0.00
- Forward P/E
- -6.94
- PEG ratio
- 0.00
- Price / sales
- 730.80
- Price / book
- 3.36
- EPS (TTM)
- -2.15
- Beta
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.20M
- Revenue growth
- 13600.00%
- Free cash flow
- -43.68M
- Total cash
- 213.01M
- Total debt
- 2.31M
- Return on equity
- -73.45%
- Shares outstanding
- 60.39M
- Short % of float
- 0.96%
- 50-day average
- 27.67
- 200-day average
- 23.22
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 51.82 +567.8% upside
Now 7.76
- Target (low)
- 42.02
- Target (mean)
- 51.82
- Target (high)
- 75.07
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.40287.
Financials — quick view
OCS Revenue — quarterly 0
OCS Net income — quarterly -9.97M
OCS EPS — quarterly -0.16
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2026 | Stifel | main | Buy | Buy |
| Jun 1, 2026 | Guggenheim | main | Buy | Buy |
| Jun 1, 2026 | Needham | main | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 21, 2026 | Guggenheim | init | — | Buy |
| May 18, 2026 | JP Morgan | main | Overweight | Overweight |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- oculis.com
News
- Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
- Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
- Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
- HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
- Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
- Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
- Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
- Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
- Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Your note
Sign in to keep a note on OCS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eqt Fund Management S.a R.l. | 10.18% | 5,900,294 | 85.61M | Mar 30, 2026 |
| Gildi - Lifeyrissjodur | 4.19% | 2,430,401 | 35.27M | Mar 30, 2026 |
| Aberdeen Group plc | 3.01% | 1,746,946 | 25.35M | Mar 30, 2026 |
| Pivotal bioVenture Partners Investment Advisor, LLC | 2.90% | 1,680,283 | 24.38M | Mar 30, 2026 |
| Wellington Management Group, LLP | 2.32% | 1,345,728 | 19.53M | Mar 30, 2026 |
| Millennium Management Llc | 1.57% | 913,034 | 13.25M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| abrdn Healthcare Opportunities Fund | 1.02% | 592,229 | 8.59M | Mar 30, 2026 |
| abrdn Healthcare Investors | 1.00% | 579,536 | 8.41M | Dec 30, 2025 |
| abrdn World Healthcare Fund | 0.61% | 355,412 | 5.16M | Mar 30, 2026 |
| abrdn Life Sciences Investors | 0.44% | 253,740 | 3.68M | Dec 30, 2025 |
| HARTFORD MUTUAL FUNDS INC/CT-THE HARTFORD HEALTHCARE FUND | 0.32% | 187,112 | 2.71M | Jan 30, 2026 |
| Global Macro Absolute Return Advantage Portfolio | 0.19% | 109,990 | 1.60M | Jan 30, 2026 |